Bard Implanted Port Catheter Products are devices used to facilitate the delivery of medications into a patient’s bloodstream. Plaintiffs allege these products are defective in that they contain barium sulfate, which reduces the integrity of the catheter and have cause injuries when surgically implanted. On October 15, 2024, the Supreme Court designated pending and future New Jersey state court litigation alleging injuries from use of Bard Implanted Port Catheter Products as multicounty litigation and assigned it for centralized management to Bergen County.